
Peruvian farmer takes on German coal giant to save his town from a melting glacier
Saúl Luciano Lliuya shudders as he looks up at the endless slabs of ice crushed haphazardly atop each other, towering majestically into the clouds.
Clinging to the flanks of Mount Palcaraju, the glacier has, like most in the Peruvian Andes, been melting rapidly in recent years, its snout retreating further and further up the precipitous expanses of jagged granite.
The influx of meltwater has led Palcacocha, a lake 5,000 feet beneath Palcaraju's summit, to swell to more than 30 times its historic volume. Now more than half-a-mile long and 200 feet deep, the lake contains 600 million cubic feet of water.
'This is not normal,' says Mr Luciano Lliuya, a semi-subsistence farmer and mountain guide, pointing to the vast talus slopes that have opened up between the glacier and the far shore of Palcacocha below. 'The glacier should come all the way down to the lake. This is so dangerous.'
As he talks, the cracking and booming of distant blocks of ice crashing unseen down the mountain rumble through the thin air. The danger Mr Luciano Lliuya is referring to is that a major avalanche could send millions of cubic feet of snow, ice and rock plummeting into the lake.
If that happens, scientists say, it could trigger a surge wave more than 60 feet high – a wave which would not stop at the water's edge, where we are standing, but instead rush down thousands of feet through a narrow mountain gorge.
Eventually, after around 30 minutes, it would slam into Huaraz, capital of the region of Ancash with around 120,000 residents. A bustling market town, Huaraz is also home to a vibrant tourist scene and draws trekkers and climbers from around the world.
That risk, and its possible relationship to climate change, is now at the heart of an unprecedented lawsuit with potentially momentous global repercussions, brought by Mr Luciano Lliuya on the other side of the planet, in Germany.
The case against the coal giant
On May 28, an appeals court in Hamm, in northwestern Germany, will rule on his civil claim against Rheinisch-Westfälisches Elektrizitätswerk (RWE), Germany's largest energy company, which is headquartered nearby. It has been burning coal at its power plants since 1900 and is one of Europe's largest emitters of greenhouse gases.
Using a property law more usually targeted at nuisance neighbours, Mr Luciano Lliuya, supported by German nonprofit Germanwatch, is demanding that RWE pay roughly €17,000 (£14,600) to the Ancash regional government towards building a protective dyke.
That corresponds to 0.47 per cent of the total cost of the dyke. It is based on the plaintiffs' calculation that RWE is responsible for 0.47 per cent of all historical carbon emissions. They argue that 50,000 people, including Mr Luciano Lliuya, live directly in the path of the potential deluge.
Filed in 2015, the case is the most advanced of several dozen similar lawsuits, brought independently in different countries around the world. Each one is being fought tooth and nail by the various corporations alleged to be fuelling climate change.
Arguably the most notable of those is one filed by the city of Honolulu, in Hawaii, against Exxon, Chevron, Shell, BP and other oil majors.
Mr Luciano Lliuya's lawsuit is therefore being watched closely by just about anyone with a stake in global climate politics, from environmental activists pushing the principle of 'the polluter pays' to the world's biggest fossil fuel companies wary of possible legal liability for extreme weather events.
'This case could set a precedent, not a binding one but a symbolic one. It could open up a flood of claims globally,' says Petra Minnerop, a law professor at Durham University, who studies climate change litigation.
'It would show that there's objectively, demonstrably attribution to a specific emitter – that this is not just about climate change generally. In that sense, this case could be very significant.'
Unsurprisingly, RWE disagrees. In a statement, it called Mr Luciano Lliuya's lawsuit 'unfounded,' said there was no risk of Palcacocha overflowing, and stressed that it had 'complied with all applicable public law regulations at all times'.
'It would be an irresolvable contradiction if the state were to regulate CO2 emissions in detail by law on the one hand and at the same time impose civil liability for them retroactively on the other,' it continued. 'Climate targets belong on the political agenda and not in a courtroom.'
Next month, the judges will either accept RWE's arguments and dismiss Mr Luciano Lliuya's claim or proceed to a forensic calculation of the monetary amount to be paid by the company.
A precedent set
The case has revolved around some highly technical details, including, for example, the low angles at which avalanches can be triggered in this part of the Peruvian Andes, thanks, in part, to their tropical latitude.
Among other factors, the court set a timeframe of 30 years for the risk to be litigable. During that period, a court-appointed expert, civil engineer Rolf Katzenbach, calculated the probability of Palcacocha devastating Huaraz at just one per cent.
But scientists advising Germanwatch, including specialists in mountain systems from universities in Switzerland and Austria, put it at 30 per cent and claim that Mr Katzenbach failed to include climate change itself in his calculations. The NGO is now asking the court to recuse Mr Katzenbach.
Possibly readying itself for an adverse result, Germanwatch is already emphasising that, whatever the judges decide on May 28, the fact that the German courts accepted the case and then allowed it to advance for a decade through the legal system is a victory.
That has already established, they say, the principle that industrial-scale carbon emitters can be sued by plaintiffs hurt by global warming far beyond the national boundaries that typically limit legal jurisdiction.
What is indisputable is that deadly avalanches and landslides naturally strike this highly-seismic region.
In 1941, around 1,800 people were killed in Huaraz – then just a tenth of the size it is today – when Palcacocha burst its banks after part of the overhanging glacier collapsed into it.
And in 1970, an earthquake triggered a landslide on Huascaran, Peru's highest peak at just over 22,000 feet, just down the valley from Huaraz. An estimated 25,000 people died – a calamity viscerally stamped into the region's collective memory.
A key question for the court is to what extent climate change elevates these risks? And then, of course, whether the blame should be apportioned to a power company nearly 7,000 miles away?
Peru is actually home to 70 per cent of the world's tropical glaciers, most of them in the Cordillera Blanca (White Range), above Huaraz. Yet they have been disappearing fast. According to the country's National Institute of Research of Mountain Glaciers and Ecosystems, 56 per cent of Peru's glacier cover has disappeared since 1962.
That means that there are, in fact, dozens of other overflowing mountain lakes in the Cordillera Blanca threatening the communities that live below them, although none on the scale of Palcacocha and Huaraz.
Peru's experience of vanishing glaciers matches the global trend. One 2023 study, in Science, found that 104,000 of the world's more than 215,000 mountain glaciers and ice caps, excluding Antarctica and Greenland, will melt away by the end of this century.
'The mountains are changing'
The symptoms of climate change in the high Andes are varied and complex. They include everything from mountain streams tinged red and made toxic by heavy metals from newly exposed rock to riskier climbing conditions as the ice weakens.
The situation is compounded by temperatures rising faster than the global average, says Alton Byers, a glaciologist at the University of Colorado, Boulder, who has been studying the Cordillera Blanca since the 1980s.
That is partly due to the albedo effect, with dark rock absorbing more of the sun's energy than the highly-reflective glaciers that once blanketed them.
'The permafrost is weakening. It's the glue that holds the mountain, or its surface, together,' Dr Byers adds. 'That is leading to an increase in avalanches and rockfall.'
Making matters worse, he says, is the fact that under the glaciers, where hard ice once gripped the rock, meltwater increasingly runs. Dr Byers is now warning that, in a worst-case scenario, even Huascaran could eventually end up without snow around a century from now.
For Mr Luciano Lliuya, the danger from Palcacocha is just the most dramatic change he is facing from global warming.
The increasingly dangerous climbing conditions means that he is losing income from his work as a mountain guide. Meanwhile, on his two-acre farm, new pests target his harvests.
His mother could store corn in ceramic pots for three years and potatoes for a year, he says.
Now both just last months, the former consumed by moths and the latter by a fungus. The trout have vanished from the streams and the once-raucous chorus of toads silenced.
'The mountains are changing. Everything is changing,' says Mr Luciano Lliuya. 'This is the most beautiful landscape, with its snow-capped summits, but I worry what will be left for my children.'
For now, the regional government has installed a system of pipes that have lowered Palcacocha by around six feet. But Cesar Portocarrera, a civil engineer and glaciologist based in Huaraz, warns that it needs to be reduced by at least 65 feet to eliminate the risk of catastrophe. It was he who first proposed the dyke, with a channel for the controlled release of excess water.
Whether that dyke is ever built in this high-altitude wilderness in a remote corner of South America – but above all who will pay for it – could have truly global implications. It will not only be Mr Luciano Lliuya and RWE who will be closely following the Hamm court's ruling next month.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New European
2 days ago
- New European
Tom Cruise, the Nietzschean Superman
The most recent instalment of the series, The Final Reckoning, involves an evil AI called 'the Entity' and nods to Dr Strangelove with its theme of nuclear jitteriness. But Tom Cruise summed it up best in a late-night show interview: 'There's a mission, and it's impossible!' And that's all you really need to know. I have seen most of the Mission: Impossible films, but I couldn't tell you much about their plots, not in any real detail anyway. The basic formula doesn't change much: retrieve a top-secret gizmo from the most impenetrable place on Earth, disarm a nuclear device with a few minutes to spare, dodge a few double-crossing agents and, from time to time, kill off the leading lady to make way for a new, younger, one. While most of us don't watch these films for their plots, what we do remember are the insane stunts: Tom Cruise climbing the Burj Khalifa, the tallest building in the world, Tom Cruise hanging onto the side of a plane as it takes off, Tom Cruise running very, very fast, Tom Cruise holding his breath under water for six minutes, Tom Cruise riding a motorbike off a mountain. Cruise famously performs all of his own stunts, a fact I was acutely aware of while watching a heart-and-show-stopping scene in The Final Reckoning, where he swings around on the wings of a biplane as it loops, dives and rolls. At one point, I turned to my partner and whispered, with a laugh of amazement, 'He's 62!' I wasn't the only one thinking it. You could feel the entire cinema tense up, everyone lifting slightly out of their seats. It was one of those cinema experiences that reminds you why going to the cinema is a thing in the first place. We weren't watching Ethan Hunt, the main character of the franchise, we were watching actor Tom Cruise push the boundaries of entertainment and of human possibility. The term 'Übermensch' comes to mind here. When the German philosopher Friedrich Nietzsche introduced the idea in the 1880s, he was thinking about how to prevent humanity from drowning in nihilism after he announced the death of God. Nietzsche imagined a superior being who could build his own values and overcome his limitations through self-determination, a creative ability to shape the world according to his will. The idea of the Superman is a wishful idea of what each of us could be, the potential to which we might be able to aspire, a better (according to the philosopher) version of humanity. This concept has been coopted, distorted and caricatured into near oblivion, and if we stretch it a little further, there is definitely a lens through which we can read both Cruise and his alter ego Ethan Hunt as embodiments of the Nietzschean Superman. Throughout the Mission: Impossible franchise, Hunt imposes his will on the chaos of the world, bending the rules of governments and institutions to enforce his own values of loyalty and justice, and, of course, to save the world. Cruise himself seems to have decided long ago that the laws of physics and of human mortality do not apply to him, and he is sometimes described as an alien, not just due to his long-standing affiliation with Scientology, but because of his apparent über-humanness. No matter your opinion of Tom Cruise, it's impossible not to be at least slightly fascinated by him. Never has someone exuded more natural charisma while seeming entirely removed from any recognisable form of human experience. It doesn't seem possible for him to exist without pushing life to its literal limits, putting himself in situations so extreme that he is likely the only person to have ever lived them. Even the way he eats popcorn reflects his desire to live to the max. The Übermensch is the one who enthusiastically says 'yes' to life, through joy as well as pain. But let's not get carried away. Nietzsche would no doubt disapprove of a hero like Hunt who operates within a traditional moral framework and whose mission isn't to transcend humanity but to preserve it. And Cruise's personal commitment to a rigid hierarchical structure like Scientology would probably not sit well with the philosopher either. When Nietzsche introduced the idea of the Übermensch, he was trying to imagine what our evolution as a species might look like. He envisioned a being as far beyond us as we are beyond our ape ancestors. Even Tom Cruise can't live up to this Nietzschean standard. But by Hollywood's standards, Cruise is the closest thing to a real Superman. I'd be willing to bet that if the stuntmen of early Westerns or the wing walkers of aviation's early days had been asked to imagine their ideal entertainer – someone as far beyond them as they were from, say, medieval jesters – they probably would have dreamed up someone like Tom Cruise. Someone who has spent years building stunts on a bigger scale than anyone in history, and continues to execute them flawlessly into his sixties, who advocates for the theatrical experience of cinema, who is credited with almost single-handedly saving the cinema industry during Covid lockdowns, and who likely influenced the Academy's decision to introduce a Stunt Design Oscar starting in 2027. A more cynical view might be that Cruise's image as the saviour of cinema, and as 'the last real movie star' is the result of a savvy PR campaign aimed at diverting from the more controversial aspects of his personal life. Whether or not that's true, there's something undeniably intoxicating about Cruise's unhinged enthusiasm, and he shows no signs of stopping. He recently said he plans to keep going well into his hundreds.

Rhyl Journal
20-05-2025
- Rhyl Journal
Vaccine maker's £1bn UK investment to create ‘hundreds of high-skilled jobs'
Biopharmaceutical company BioNTech has announced funding of up to £1 billion into the UK over the next 10 years. The planned investment would be one of the biggest in the history of UK life sciences, the Department for Science, Innovation and Technology said. As part of plans to increase its UK presence, the vaccine maker will create two new research and development hubs – one in Cambridge, and an AI hub at its planned UK headquarters in London. The centres could create more than 400 new jobs over the next 10 years including researchers in clinical and scientific drug development. As part of the agreement, the Government will contribute up to £129 million over the same period. German-based BioNTech developed mRNA vaccines and cancer immunotherapies, notably used to tackle Covid-19. Science and Technology Secretary Peter Kyle said the investment would boost the economy. 'This investment will propel the growth-driving life sciences sector to new heights, delivering cutting-edge facilities, building careers in the future-facing jobs we want our children to have, and ultimately unlocking progress in medical science that could save lives,' he said. 'This is a clear indication of how we will deliver the Government's Plan for Change: working together with the best and brightest businesses and innovators to unlock their potential, and then reap the benefits for the economy, health and more that their drive and genius can deliver.' Chancellor Rachel Reeves said: 'This is another testament to confidence in Britain being one of the world's top investment destinations and a global hub for life sciences. 'It will create hundreds of high-skilled, well-paid jobs, as we deliver on our promise to put more money in working people's pockets through our Plan for Change.' The CEO and co-founder of BioNTech, Ugur Şahin, said the agreement 'marks the next chapter of our successful strategic partnership with the UK Government'.


Daily Mirror
20-05-2025
- Daily Mirror
Record deal with jab-maker BioNTech could see UK become science 'superpower'
Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and prevent cancers before they develop Britain could become the global 'superpower' at treating disease, the Government says. The UK will today sign a new billion pound deal with drugmaker BioNTech to pioneer mRNA technology to fight the next pandemic and prevent cancers. The Covid jab-maker is investing £1 billion to set up three centres of excellence in the UK which will also use artificial intelligence (AI) to develop new drugs here for a range of diseases. Science and Technology Secretary Peter Kyle told the Mirror: 'There are two totally transformative technologies coming together - mRNA as a tool for vaccines plus artificial intelligence. We as a country can be not just a leading force, but the superpower that the world needs when it comes to treating disease.' BioNTech, in collaboration with Pfizer, was the first company to develop an mRNA vaccine against Covid-19, which became the main vaccine used in Britain during the pandemic. Traditionally, vaccines inject a weakened or deactivated form of a virus to help the body's immune system recognise it so that when it comes into contact with a genuine infection it can fight it off. The mRNA technology does not use any virus but instead delivers genetic instructions to train the immune system to identify the virus's spike protein. This meant it was deemed to be safer and less likely to cause side effects. The same technology is now being used to develop cancer vaccines which help the body recognise and kill cancer cells. They could even be given to people at genetic risk of specific cancers to prevent tumour developing. Mr Kyle said: 'The Holy Grail is always stopping people getting cancer in the first place and mRNA treatments are preventative. We are in the foothills of the age where we could be treated for diseases that are not currently present in our bodies and actually the technology is leading in that direction faster than people realise. This is something that this government wants to be at the forefront of so it is British people who benefit first, while we also contribute to the global good.' BioNTech is aiming to provide 10,000 UK patients with personalised cancer immunotherapies, tailored to their individual genetic risk, by 2030. It comes after the previous government signed a ten-year deal with the other big mRNA pharmaceutical firm Moderna in 2022, which last week opened its new manufacturing lab in Oxfordshire. German multinational BioNTech will now start work setting up centres of excellence in Cambridge, London and a yet-to-be-confirmed third location. The London site will be a major hub to research AI to enhance our understanding of diseases, their causes and how drugs could target them. Mr Kyle said: 'This is a foundational technology that could be applied in ways that we can't even imagine right now. AI knows everything. It has consumed every scientific experiment in certain areas that has ever taken place and it can bring all of that information to bear. That means that its ability to solve problems using patterns and ideas using potential chemicals or existing drugs… is infinite. 'Imagine computer programs that actually have almost all information in it and are able to harness it and throw this information at new challenges. Then you get a glimpse of the era that we are now stepping into as humanity. How exciting it should be, and how much pride we should all take, that Britain is leading the way.' How does mRNA work? (by Health and Science Editor Martin Bagot) Messenger RNA (mRNA) has been described as a bit like developing a wanted poster for our immune system. Britain has made a huge investment in mRNA capabilities to protect the population from future pandemic and better treat existing diseases. It uses genetic code to create an immune response by giving the body the instructions to protect against a certain virus or disease. Such vaccines have the potential to be repurposed at speed when combined with the vast genetic knowledge which can be harnessed by AI. Once the design has been proven then a different face to the wanted poster - or a different set of genetic instructions - can be slotted in easily. Vaccines which help prime the body's immune system to stop cancers returning are already here. The next step will be to develop personalised vaccines for people at high genetic risk of cancer to stop it developing in the first place. At a third site, to be announced shortly, BioNTech will research vaccines including for diseases with high pandemic potential. To help get the deal with BioNTech the Government agreed to contribute £129 million in grant funding over the next ten years. The UK life sciences sector is worth over £100 billion in turnover annually in the UK and supports 304,000 jobs in 6,850 businesses. Chancellor Rachel Reeves said:'This is another testament to confidence in Britain being one of the world's top investment destinations and a global hub for life sciences. It will create hundreds of high-skilled, well-paid jobs, as we deliver on our promise to put more money in working people's pockets through our Plan for Change.' BioNTech co-founder Uğur Şahin said: 'This agreement marks the next chapter of our successful strategic partnership with the UK Government. Together, we have already made a meaningful difference in expanding access to investigational personalized cancer therapies for patients. Now we are taking the next step to accelerate and broaden our research and development efforts advancing towards our vision to translate science into survival for patients.' Steve Bates, CEO of the UK BioIndustry Association, said: 'BioNTech's investment demonstrates the UK's position as a top destination for life sciences innovation and underlines why the government is absolutely right to back our sector as a priority for growth. BioNTech is not only a pioneer in mRNA science, but also a visionary partner in building a truly unique public-private collaboration with the UK Government and NHS – one that sets a benchmark for the world. 'The UK has a once-in-a-lifetime opportunity to leverage its strong position to attract investment from global investors to create well-paid jobs and scale UK companies, if the upcoming Life Sciences Sector Plan can address long-standing structural challenges in the financing and commercial environment.' Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI), said: 'This investment is a testament to the fantastic skills, research capabilities, and scientific infrastructure we have in the UK. It is also a template for how the UK could unlock further life science sector growth by removing the barriers and roadblocks to investment. 'Big investments like this are years in the making and require both sides to have confidence that the other will deliver on their commitments. Trust is slow to build, but this deal shows it is worth the time and the risk. 'Life science companies are already the largest investors in UK R&D – but much of this comes from a handful of companies with deep UK roots. The UK has an opportunity to capture more of the global science pie if we can improve our competitive offering to the sector.'